App-Quantinova.ai

Results From the Dose Escalation Phase of a Randomized Phase 12 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Hagop M. Kantarjian - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Thrombocytopenia

Vidaza

Genetic Variability of the CLEC4M Endothelial Lectin Receptor Modulates Binding and Internalization of Von Willebrand Factor and Contributes to Variance in Plasma VWF Levels

Natalia Rydz - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

FVIII

Management and Outcomes of Major Bleeding On Dabigatran or Warfarin

Hun-Gyu Hwang - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Prothrombin complex

Time Course Studies of the Progeny of Barcoded CD34+ Human Cord Blood Cells Generated in Transplanted NOD/SCID-IL2R??/? Mice Unveil the Clonal Dynamics of Short Term, Intermediate Term and Long Term Repopulating Cells

Long V. Nguyen - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Hematopoietic Stem Cell Expansion, without Exhaustion or Transformation, by Stable Microrna Antagonism in Vivo

Alice Giustacchini - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Adrucil injection

Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up

David Baanstra - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Pradax

STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML)

Ira L Kraft - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Imatinib

Effects of Dabigatran and Rivaroxaban On Routine and Specialized Coagulation Assays: A Study Using Actual Patient Plasma Samples

Leslie Zypchen - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

rivaroxaban

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Michael Lubbert - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastrointestinal syndrome

Cytarabine liposomal

A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial

Stan Shapiro - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Deep vein thrombosis

N/A

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ian W. Flinn - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-Cell Non-Hodgkin Lymphoma

monomethyl auristatin E

The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

Michael Pfreundshuh - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Bevacizumab

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Hagop M. Kantarjian - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

Norman Franke - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Monoclonal gammopathy

Thalidomide

Thymocyte Reprogramming by the Scl, Lmo1 and Notch1 Oncogenes

Cedric Stevens Tremblay - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute lymphoblastic leukemia

N/A

Ivig, but Not a Monoclonal Anti-RBC Antibody, Requires the Presence of Gr-1+ Cells to Ameliorate Immune Thrombocytopenia in a Murine Model

Alan H Lazarus - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Immune thrombocytopenia

IVIG

Desialylation: A Novel Platelet Clearance Mechanism and a Potential New Therapeutic Target in Anti-GPIb Antibody Mediated Thrombocytopenia

Guangheng Zhu - American Society of Hematology (ASH) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Phosphatidylserine

The UK LORIS trial: Randomizing patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

A Francis - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with mutant tumors

J Baselga - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

E Hamilton - San Antonio Breast Cancer Symposium (SABCS) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab emtansine

Filters

28841 Abstracts